- Home
- OUT vs GERN Comparison
OUT vs GERN Comparison
Compare OUT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUT
- GERN
- Stock Information
- Founded
- OUT 2013
- GERN 1990
- Country
- OUT United States
- GERN United States
- Employees
- OUT N/A
- GERN N/A
- Industry
- OUT Real Estate Investment Trusts
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- OUT Real Estate
- GERN Health Care
- Exchange
- OUT Nasdaq
- GERN Nasdaq
- Market Cap
- OUT 2.9B
- GERN 2.5B
- IPO Year
- OUT N/A
- GERN 1996
- Fundamental
- Price
- OUT $18.94
- GERN $2.89
- Analyst Decision
- OUT Hold
- GERN Strong Buy
- Analyst Count
- OUT 6
- GERN 10
- Target Price
- OUT $19.00
- GERN $7.15
- AVG Volume (30 Days)
- OUT 1.6M
- GERN 14.8M
- Earning Date
- OUT 02-19-2025
- GERN 02-26-2025
- Dividend Yield
- OUT 4.76%
- GERN N/A
- EPS Growth
- OUT N/A
- GERN N/A
- EPS
- OUT 1.41
- GERN N/A
- Revenue
- OUT $1,838,900,000.00
- GERN $29,480,000.00
- Revenue This Year
- OUT N/A
- GERN $31,478.06
- Revenue Next Year
- OUT $1.95
- GERN $290.89
- P/E Ratio
- OUT $13.40
- GERN N/A
- Revenue Growth
- OUT 1.37
- GERN 9199.68
- 52 Week Low
- OUT $12.57
- GERN $1.64
- 52 Week High
- OUT $19.98
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- OUT 59.01
- GERN 25.84
- Support Level
- OUT $17.17
- GERN $2.80
- Resistance Level
- OUT $18.29
- GERN $3.68
- Average True Range (ATR)
- OUT 0.48
- GERN 0.18
- MACD
- OUT 0.08
- GERN -0.04
- Stochastic Oscillator
- OUT 83.48
- GERN 10.23
About OUT OUTFRONT Media Inc.
Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The Company generates revenue in the form of rental income by allowing other companies to advertise on its properties and structures under short-term contracts. Outfront Media segments its operations into the United States and International units. Although it also owns assets in Canada and Latin America, the company derives the vast majority of its revenue from billboard advertising agreements in the U.S. Roughly half of the U.S. division's revenue comes from its displays in the New York City and Los Angeles markets. Outfront Media's major customers include entities within the retail, television, healthcare, and entertainment industries.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.